Case Report: Genetic predisposition to low-dose NSAID-induced liver injury in real-world China

Non-steroidal anti-inflammatory drug (NSAID)-induced liver injury represents approximately 10% of reported drug-induced liver injury (DILI) cases, predominantly through idiosyncratic mechanisms. While epidemiological data are largely derived from Western populations with high NSAID utilization, Chin...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Yuan Lyu, Yangjie Li, Yingying Jiang, Qi Li, Chen Shao, Chunlei Fan, Ying Han, Hui Liu, Lingna Lyu, Huiguo Ding
פורמט: Article
שפה:אנגלית
יצא לאור: Frontiers Media S.A. 2025-07-01
סדרה:Frontiers in Medicine
נושאים:
גישה מקוונת:https://www.frontiersin.org/articles/10.3389/fmed.2025.1637289/full
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
_version_ 1839618294992076800
author Yuan Lyu
Yangjie Li
Yingying Jiang
Qi Li
Chen Shao
Chunlei Fan
Ying Han
Hui Liu
Lingna Lyu
Huiguo Ding
author_facet Yuan Lyu
Yangjie Li
Yingying Jiang
Qi Li
Chen Shao
Chunlei Fan
Ying Han
Hui Liu
Lingna Lyu
Huiguo Ding
author_sort Yuan Lyu
collection DOAJ
description Non-steroidal anti-inflammatory drug (NSAID)-induced liver injury represents approximately 10% of reported drug-induced liver injury (DILI) cases, predominantly through idiosyncratic mechanisms. While epidemiological data are largely derived from Western populations with high NSAID utilization, China exhibits lower use of NSAIDs due to cultural preferences and the widespread use of traditional therapies. During the 2022–2023 Omicron outbreak in China, we observed a surge in DILI cases coinciding with increased NSAID use. This study reports two young male patients who developed severe cholestatic DILI following low-dose ibuprofen intake (400 mg), despite lacking conventional risk factors. Genetic analysis revealed compound heterozygous mutations in ABCB11 (encoding the bile salt export pump, BSEP), including the known risk variant p.V444A and the synonymous SNP p.A1028A, with Patient 1 harboring an additional p.A865V mutation. Immunohistochemistry demonstrated abnormal BSEP expression patterns—reduced membrane localization in Patient 2 and intracellular retention in Patient 1—mirroring the pathological features of progressive familial intrahepatic cholestasis type 2 (PFIC-2). These findings suggest that NSAIDs may unmask latent BSEP dysfunction in genetically predisposed individuals, precipitating refractory cholestasis. Our study highlights ABCB11 polymorphisms as critical determinants of NSAID-related DILI susceptibility, even at therapeutic doses. In addition, we propose mechanistic insights into BSEP dysfunction-mediated cholestasis and emphasize pharmacogenetic considerations in NSAID safety assessment across populations.
format Article
id doaj-art-52e4487b476f460ba1183967ea1035ed
institution Matheson Library
issn 2296-858X
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Medicine
spelling doaj-art-52e4487b476f460ba1183967ea1035ed2025-07-24T06:16:24ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-07-011210.3389/fmed.2025.16372891637289Case Report: Genetic predisposition to low-dose NSAID-induced liver injury in real-world ChinaYuan LyuYangjie LiYingying JiangQi LiChen ShaoChunlei FanYing HanHui LiuLingna LyuHuiguo DingNon-steroidal anti-inflammatory drug (NSAID)-induced liver injury represents approximately 10% of reported drug-induced liver injury (DILI) cases, predominantly through idiosyncratic mechanisms. While epidemiological data are largely derived from Western populations with high NSAID utilization, China exhibits lower use of NSAIDs due to cultural preferences and the widespread use of traditional therapies. During the 2022–2023 Omicron outbreak in China, we observed a surge in DILI cases coinciding with increased NSAID use. This study reports two young male patients who developed severe cholestatic DILI following low-dose ibuprofen intake (400 mg), despite lacking conventional risk factors. Genetic analysis revealed compound heterozygous mutations in ABCB11 (encoding the bile salt export pump, BSEP), including the known risk variant p.V444A and the synonymous SNP p.A1028A, with Patient 1 harboring an additional p.A865V mutation. Immunohistochemistry demonstrated abnormal BSEP expression patterns—reduced membrane localization in Patient 2 and intracellular retention in Patient 1—mirroring the pathological features of progressive familial intrahepatic cholestasis type 2 (PFIC-2). These findings suggest that NSAIDs may unmask latent BSEP dysfunction in genetically predisposed individuals, precipitating refractory cholestasis. Our study highlights ABCB11 polymorphisms as critical determinants of NSAID-related DILI susceptibility, even at therapeutic doses. In addition, we propose mechanistic insights into BSEP dysfunction-mediated cholestasis and emphasize pharmacogenetic considerations in NSAID safety assessment across populations.https://www.frontiersin.org/articles/10.3389/fmed.2025.1637289/fullnon-steroidal anti-inflammatory drugsibuprofendrug-induced liver injuryBSEP (ABCB11)genetic predisposition
spellingShingle Yuan Lyu
Yangjie Li
Yingying Jiang
Qi Li
Chen Shao
Chunlei Fan
Ying Han
Hui Liu
Lingna Lyu
Huiguo Ding
Case Report: Genetic predisposition to low-dose NSAID-induced liver injury in real-world China
Frontiers in Medicine
non-steroidal anti-inflammatory drugs
ibuprofen
drug-induced liver injury
BSEP (ABCB11)
genetic predisposition
title Case Report: Genetic predisposition to low-dose NSAID-induced liver injury in real-world China
title_full Case Report: Genetic predisposition to low-dose NSAID-induced liver injury in real-world China
title_fullStr Case Report: Genetic predisposition to low-dose NSAID-induced liver injury in real-world China
title_full_unstemmed Case Report: Genetic predisposition to low-dose NSAID-induced liver injury in real-world China
title_short Case Report: Genetic predisposition to low-dose NSAID-induced liver injury in real-world China
title_sort case report genetic predisposition to low dose nsaid induced liver injury in real world china
topic non-steroidal anti-inflammatory drugs
ibuprofen
drug-induced liver injury
BSEP (ABCB11)
genetic predisposition
url https://www.frontiersin.org/articles/10.3389/fmed.2025.1637289/full
work_keys_str_mv AT yuanlyu casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina
AT yangjieli casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina
AT yingyingjiang casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina
AT qili casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina
AT chenshao casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina
AT chunleifan casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina
AT yinghan casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina
AT huiliu casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina
AT lingnalyu casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina
AT huiguoding casereportgeneticpredispositiontolowdosensaidinducedliverinjuryinrealworldchina